ADX-629 for Ethanol Intoxication

Phase-Based Progress Estimates
Medpace Clinical Pharmacology, Cincinnati, OH
Ethanol Intoxication
ADX-629 - Drug
All Sexes
What conditions do you have?

Study Summary

A Double-Blind Trial to Assess the Interaction Between ADX-629 and Ethanol While Exploring the Safety, Tolerability, and Activity of ADX-629 in Subjects With Elevated Ethanol Levels

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Ethanol Intoxication

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: In the two days of each Cycle (each cycle is 2 days)

Day 2
Assessment of symptoms using the Alcohol Toxicity Symptom Scale
Assessment of symptoms using the Clinical Global Impression - Impairment Severity Scale
Assessment of symptoms using the Global Impression Visual Analog Scale

Trial Safety

Safety Progress

1 of 3

Other trials for Ethanol Intoxication

Trial Design

2 Treatment Groups

ADX-629 Oral Tablets
1 of 2
1 of 2
Experimental Treatment
Non-Treatment Group

30 Total Participants · 2 Treatment Groups

Primary Treatment: ADX-629 · Has Placebo Group · Phase 1 & 2

ADX-629 Oral Tablets
Experimental Group · 1 Intervention: ADX-629 · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: in the two days of each cycle (each cycle is 2 days)
Closest Location: Medpace Clinical Pharmacology · Cincinnati, OH
Photo of Cincinnati 1Photo of Cincinnati 2Photo of Cincinnati 3
2014First Recorded Clinical Trial
1 TrialsResearching Ethanol Intoxication
8 CompletedClinical Trials

Who is running the clinical trial?

Aldeyra Therapeutics, Inc.Lead Sponsor
27 Previous Clinical Trials
3,687 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are between the ages of 21 and 65 years, inclusive.
Subjects must be able to obtain transportation to and from the study site.
Subjects who agree to abstain from consumption of non-study alcohol during the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.